ImpriMed to Showcase Groundbreaking AI Research and Applications at Symposium on Artificial Intelligence in Veterinary Medicine (SAVY)
Business Wire
Learn More →ImpriMed to Present Innovative Research at 2024 World Veterinary Cancer Congress
Business Wire
Learn More →ImpriMed Raises $23 Million Series A Round to Expand its Revolutionary AI-Powered Cancer Treatment Technology
Business Wire
Learn More →ImpriMed Celebrates the Milestone of 4,000 Dog Blood Cancer Patients
Business Insider
Learn More →ImpriMed Wins Place at the Mayo Clinic Platform_Accelerate Immersive Program
EIN Presswire
Learn More →40 Under 40 in Cancer Class of 2022 Recognizes Dr. Sungwon Lim, ImpriMed CEO & Co-Founder
EIN Presswire
Learn More →ImpriMed Presents New Research Findings at The Veterinary Cancer Society (VCS) Mid-Year Conference
EIN Presswire
Learn More →ImpriMed AI and machine learning is disrupting the veterinary oncology tools available for better treatment outcomes
EIN Presswire
Learn More →ImpriMed Publishes Exclusive Canine Patients Data Analysis
EIN Presswire
Learn More →ImpriMed CEO and Co-founder Dr. Sungwon Lim Wins Prestigious “Top Industry Leader” Award from Life Sciences Voice
EIN Presswire
Learn More →ImpriMed Reports Significant Growth in 2021 with Pre-Series A Funding, New Product Launches, and Team Expansion
EIN Presswire
Learn More →ImpriMed Launches New Diagnostic Services for Canine Lymphoma
EIN Presswire
Learn More →ImpriMed Initiates Feline Lymphoma Drug Response Prediction Study
EIN Presswire
Learn More →ImpriMed Launches Chemo Response Prediction and Immunophenotyping Services for Canine Lymphoma
GlobeNewswire
Learn More →ImpriMed Raises $8M to Commercialize AI-Driven Personalized Drug Response Prediction Service in Pet Cancer Market
GlobeNewswire
Learn More →ImpriMed Launches Advanced Precision Medicine Service for Canine Blood Cancers
PR Underground
Learn More →ImpriMed Raises $4M for Customized Cancer Treatments for Dogs
GlobeNewswire
Learn More →